List of Abilify drug patents

Abilify is owned by Otsuka.

Abilify contains Aripiprazole.

Abilify has a total of 20 drug patents out of which 9 drug patents have expired.

Expired drug patents of Abilify are:

  • US8642600
  • US9089567
  • US7053092
  • US6977257
  • US8642600*PED
  • US6977257*PED
  • US9359302
  • US8580796
  • US8642760

Abilify was authorised for market use on 07 June, 2006.

Abilify is available in tablet, orally disintegrating;oral dosage forms.

Abilify can be used as treatment of major depressive disorder (mdd), treatment of irritability associated with autistic disorder, acute treatment of manic and mixed episodes associated with bipolar i disorder, treatment of schizophrenia, adjunctive treatment of major depressive disorder (mdd), treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder.

The generics of Abilify are possible to be released after 02 March, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642600 OTSUKA Method of treating autism
Jan, 2022

(1 year, 1 day ago)

US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 1 day ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 1 day ago)

US6977257 OTSUKA Aripiprazole oral solution
Apr, 2022

(9 months ago)

US8642600

(Pediatric)

OTSUKA Method of treating autism
Jul, 2022

(6 months ago)

US6977257

(Pediatric)

OTSUKA Aripiprazole oral solution
Oct, 2022

(3 months ago)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(a month from now)

US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(a month from now)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(10 months from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 4 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(1 year, 10 months from now)

US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 11 months from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 11 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(3 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(4 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia; Treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic